Jean Francois Chatal
Jean Francois Chatal is a Distinguished Professor of nuclear medicine at the University of Nantes, France. In 1975, he created a research team devoted to diagnostic (scintigraphic imaging) and therapeutic (radioimmunotherapy) use of radio-labeled monoclonal antibodies in oncology. This research team was a part of a larger group specialized in immunology and oncology and affiliated to the National Institute of Health and Medical Research (INSERM) and the University of Nantes.The first patient with a colorectal carcinoma was injected in Nantes with a 131I-labeled antitumor monoclonal antibody in June 1981. At the end of the 1980s, he developed a strong collaboration with Immunotech company in Marseille for the preclinical and clinical application of an original and innovative pretargeting technology based on the use of unlabeled bispecific antibody and radiolabeled bivalent hapten and which had just been patented by Immunotech. After a clear documentation of the efficacy of this technology in diagnostic application (immunoscintigraphy) at the begining of the 1990s, the first phase I radioimmunotherapy study was initiated in 1996 in patients with medullary thyroid cancer and small cell lung cancer. Recently, in 2006, a paper published in the Journal of Clinical Oncology reported, for the first time, a survival benefit of pretargeted radioimmunotherapy in an advanced solid tumor (medullary thyroid carcinoma). Chatal initiated, with 2 other colleagues, the project of installation in Nantes in 2008, of a high-energy/high-intensity cyclotron, termed ARRONAX, for the production of innovative radionuclides for diagnostic and therapeutic nuclear medicine research in Europe. He wrote 180 original papers and presented more than 100 invited lectures.
Biography Updated on 28 January 2010